10 November 2021 LungLife AI, Inc. ("LungLife" or the "Company") Block Listing Application LungLife AI (AIM: LLAI), the developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces that a block listing application (the “Block Admission”) has been made to the London Stock Exchange for up to 1,356,139 common shares of US […]
12 October 2021 LungLife AI, Inc. (the “Company” or “LungLife”) PLA Code application submitted in first step in reimbursement process LungLife AI (AIM: LLAI), a developer of clinical diagnostic solutions for lung cancer enhanced by artificial intelligence, announces it has submitted its application for a Proprietary Laboratory Analysis (PLA) code to the American Medical […]
LungLife AI licensure/accreditation information posted here.